Exact Sciences Rises After Key FDA Win

By Investor's Business Daily | Oct 4, 2024 at 10:41 AM EST

Exact Sciences saw a rise in stock value after FDA approval of its Cologuard Plus colon cancer test. The test is highly sensitive and specific, with potential to detect precancerous lesions. Analysts expect positive outcomes for the company due to Medicare reimbursement opportunities and potential guideline updates.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.